arge-scale study of proteins in triple negative breast cancer patients.
Not Applicable
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2022/05/042696
- Lead Sponsor
- Government Ministry of Human Resources and Development Uchchatar Avishkar Yojana
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Histologically confirmed TNBC
2. Treatment naive
3. Tumour and adjacent normal tissue sample preserved by TMH/ACTREC Tumour Tissue Repository
4. Patient consented for study by TMH/ACTREC Tumour Tissue Repository
5. Patient already consented for IEC Study 254 : A prospective approval of the peri-operative Hypoxia in
breast cancer (Sample B study) & tissue available for OMICS assays
Exclusion Criteria
1. Patients who have received any form of prior treatment
2. Patients not consented by TMH/ACTREC Tumour Tissue Repository or on IEC Study 254
3. Patients whose clinical history is not available
4. Patients for whom paired normal tissue or blood is not collected
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method sing a patient centric and patient specific multi-omics approach to holistically characterize <br/ ><br>molecular programs involved in development of Triple Negative Breast Cancer (TNBC).Timepoint: 12 months
- Secondary Outcome Measures
Name Time Method ot applicableTimepoint: Not applicable